Endocyte, Inc.ECYT was a big mover last session, as the company saw its shares rise over 11% on the day. The upside was driven by the announcement of narrower-than expected third-quarter 2015 loss by the company. This also led to far more shares changing hands than in a normal session. This breaks the recent trend for the company, as the stock is now trading above the volatile price range of $4.37 to $4.90 in the past one-month time frame.
The company has not seen any estimate revision in the past 30 days and its Zacks Consensus Estimate also remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Endocyte currently has a Zacks Rank #3 (Hold).
A better-ranked med-drugs stock is Concordia Healthcare Corp. CXRX with a Zacks Rank #1 (Strong Buy).
Is ECYT going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ENDOCYTE INC (ECYT): Free Stock Analysis Report
CONCORDIA HLTHC (CXRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
